Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
Tuesday, September 01, 2015 7:25:07 AM
"What is the "New Science", proves TG reduction decreases CVE?"
Ah "that is the Question"
Shakespeare
OK..Let's establish parameters..The first is the question is not a mathematical proof which would not be open to opinion. The speed of light does not need the defense of opinions.
Very crucial to the question is was the "New Science" used by the FDA to rescind the SPA, valid. The idea behind the SPA is to put FDA and the sponsor on a more even level. The FDA's decision in rescinding the SPA was unilateral and the theory of contracts is that both partners are allowed to express their opinion and if there is a serious disagreement, then the case can be taken before a neutral arbitrator (eg. the courts) for dispute resolution. In this case the FDA is acting as both a combatant and the arbitrator. They have also managed to trample Amarin's rights by a well devised stalling technique which the federal courts ought to take a look at as it clearly violates constitutional right to speedy trial.
New science?? The question does lowering trigs lower CVD risk is controversial. Supporting evidence suggests trig lowering should lower CVD risk simply because trigs are part of the non HDL-C lipid fraction and the literature says that non-HDL-C is a better predictor of CVD risk than LDL-C. Trig levels also effect the configuration of LDL-C and higher trig levels move the particles toward the small dense variety which raises LDL-P. LDL-P is considered the best predictor of CVD risk.
On the other side, skeptics say trigs are not independent predictors of CVD risk if you factor in non HDL-C...This is the kind of nonsense argument that suggest there are too many English majors in medicine and not enough science majors.
So the question is really not about "New Science", because the SPA rescission decision was not about "New Science". If there was truly new science then Amarin would have been forced to agree...something that has not happened. Entering the SPA agreement both sides understood the trig question was controversial. If the answer were known, then what could be the rationale for running REDUCE-IT. To cancel the SPA in a manner that would hold up in a neutral court, the FDA would have had to introduce evidence that trig lowering would not lower CVD risk...Something they attempted in their pathetic "three Trig Study" presentation. Their argument was absurd.
So the SPA was rescinded without meeting the New Science bar. They simply used their authority. This really was nothing different than a school bully taking another kid's lunch money. So the FDA was free to make its own determination, and now it is equally free to change its mind..New Science is not a mathematical term...We know from bitter experience, that New Science is what the FDA says it is...
Everything boils down to Aesop's Fables...
"The Fox, the wolf and the lion"
A fox a wolf and a lion have killed a deer and the lion asks the wolf to divide the carcass up between the three. The wolf carefully divides the the meat into three equal portions. At this point the lion jumps on the wolf and kills him. The lion then turns to the fox and asks him to divide the kill. The fox gives himself a tiny portion of the meat, and the rest to the lion. After eating the lion asks the fox how he learned to divide up the spoils so well. The Fox answered.."I learned it from the dead wolf".
":>) JL
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM